Business highlights in Q4 2021
- On October 1st the result of the long-term incentive program (“LTI2021”) was published
- On October 8th the conditional approval for listing on Nasdaq First North was announced
- On October 18 it was announced that a CTA for a Phase 1 study in relation to assessment of pain reducing effects with IP2015 had been filed
- On October 25th the trading of Initiator Pharma shares on Nasdaq First North commenced
- On November 25th the approval of the CTA for a Phase 1 study in relation to assessment of pain reducing effects with IP2015 was announced
- On December 25th an update on the clinical programs was announced
Business highlights after this reporting period
- On January 20th the first dosing of subjects in the Phase 1 study in relation to assessment of pain reducing effects with IP2015 was announced
Financial Highlights
| Fourth Quarter (2020-10-01 – 2020-12-31) |
| Net revenues were TDKK 0 (0) |
| Operating loss, EBIT was TDKK -7 280 (-2 069) |
| Earnings per share was DKK –0.32 (-0.01) |
| Full Year (2020-01-01 – 2020-12-31) |
| Net revenues were TDKK 0 (0) |
| Operating loss, EBIT was TDKK -23 072 (-10 531) |
| Earnings per share was DKK –0.48 (-0.31) |
| Cash and bank: TDKK 34,346 (13,504) |
| Solidity: 65% (92%) |
Solidity: equity divided by assets.
Link to the full report
https://www.initiatorpharma.com/en/investors/reports-and-presentations/